Shilpa Biocare, a fully-owned subsidiary of Shilpa Medicare, announces ahead of BIO Boston that it has secured a Europe-wide commercial supply agreement with Orion Corporation for Recombinant Human Albumin.
Alex Tao Wang Shutterstock
Boston, Massachusetts, USA.
Shilpa’s Recombinant Human Albumin – a key plasma protein used in various therapeutic applications – is currently under development and will be manufactured using a robust non-human expression system. This provides improved safety, scalability, and virus-free production, addressing some of the key limitations associated with human-derived albumin.
Under the terms of the agreement, Orion will gain exclusive rights to distribute, market and sell Shilpa’s Recombinant Human Albumin in Europe, with Shilpa receiving development and regulatory milestone payments from Orion.
“We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,” said Satu Ahomäki, EVP generics and consumer health, Orion Corporation. “Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.”
At BIO Boston, Shilpa is expected to see increased interest from biopharma innovators, particularly smaller biotech firms, leveraging its development capabilities in oncology and biologics – with the CDMO having both commercial facilities for both mammalian and microbial production.
Madhav Bhutada, managing director, Shilpa Biocare, said: “Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market. This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.”